Deckers (DECK) was downgraded to neutral at Citigroup. $53 price target. The company is seeing further wholesale decline, Citi said.
Ionis Pharmaceuticals (IONS - Get Report) was downgraded to market perform from outperform at BMO Capital. $26 price target. Trial delay reduced sales projections and probability of success, BMO said.
Signet Jewelers (SIG - Get Report) was downgraded to neutral from buy at Goldman Sachs. $119 price target. The company was also removed from the Conviction Buy list, as comp-store sales growth is slowing, Goldman said.
Synergy Resources (SYRG) was upgraded to buy from hold at Cantor Fitzgerald. $7.50 price target. Earnings estimates were also increased, given its high-graded footprint in the Wattenberg Fairway, Cantor said.